In addition, we show that combinations of CSF1R inhibitors with tumor-directed therapies in CLL (ibrutinib or idelalisib) exhibit strong synergy across numerous CLL patient specimens (Figure 5). This evidence concerns the gene CSF1R and neoplasm.